Impact of steroid therapy on pediatric acute liver failure: prognostic implication and interplay between TNF-α and

Rania M El-Shanawany1, Eman A El-Maadawy2, Hanaa A El-Araby1

  • 1Pediatric Hepatology, Gastroenterology, and Nutrition Department, National Liver Institute, Menoufia University, Menoufia, Shebin El-Koom, 32511, Egypt.

PubMed

Insights

Lower miR-122 levels in children with acute liver failure treated with steroids correlate with better outcomes. This microRNA, along with increased TNF-α, plays a role in disease progression and may aid in prognosis.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Molecular Biology

Background:

  • Acute liver failure (ALF) presents a significant risk in children, with limited evidence on steroid efficacy.
  • MicroRNA-122 (miR-122) is a key player in liver function and disease, showing altered expression in various liver conditions.
  • miR-122 is explored as a potential biomarker for disease progression, prognosis, and therapeutic targeting in liver diseases.

Purpose of the Study:

  • To evaluate miR-122 expression in pediatric ALF patients before and after steroid therapy.
  • To investigate the relationship between miR-122, tumor necrosis factor-alpha (TNF-α), and treatment response in ALF.
  • To assess miR-122's potential as a biomarker for predicting outcomes in pediatric ALF.

Main Methods:

  • Serum samples from 24 children with ALF were analyzed.
  • miR-122 levels were quantified using quantitative real-time RT-PCR (qRT-PCR).
  • TNF-α levels were measured via enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • Surviving ALF children showed significantly decreased miR-122 levels post-steroid treatment compared to pre-treatment and deceased patients.
  • TNF-α levels were significantly elevated in surviving patients post-steroid treatment compared to pre-treatment and deceased children.
  • A negative correlation was found between TNF-α and miR-122 post-steroids (r=-0.46, p=0.04), and miR-122 showed 72% sensitivity and 67% specificity in distinguishing survivors.

Conclusions:

  • Lower miR-122 levels in pediatric ALF patients treated with steroids are associated with improved outcomes.
  • While not a standalone marker, miR-122 may be valuable as part of a biomarker panel for ALF.
  • Elevated TNF-α and reduced miR-122 suggest their involvement in ALF pathophysiology, warranting further investigation.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142